NEWARK, Del, March 20, 2023 (GLOBE NEWSWIRE) -- During the forecast period 2023 to 2033, the Hepatic Encephalopathy Treatment Market is expected to grow at a value of 6.5% CAGR, according to Future Market Insights. By the year 2033, the global market for Hepatic encephalopathy treatment is expected to rise up to a market valuation of US$ 2971.51 Million. Growth of the market can be attributed to increasing prevalence of liver diseases such as cirrhosis and non-alcoholic fatty liver disease (NAFLD).
One of the key factors driving the growth of the Hepatic Encephalopathy Treatment Market is the development of new and innovative treatments for HE. In recent years, several new medications have been approved for the treatment of HE, including rifaximin, lactulose, and neomycin. These medications work by reducing the levels of toxins in the gut or preventing their absorption into the bloodstream, which can help reduce the severity of HE symptoms.
For details on vendors and their offerings – Request a sample report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16814
Another factor driving the growth of the Hepatic Encephalopathy Treatment Market is the increasing awareness and diagnosis of HE. As the prevalence of liver diseases such as cirrhosis and NAFLD continues to rise, more individuals are being diagnosed with HE and seeking treatment. In addition, advancements in diagnostic technologies have made it easier for healthcare professionals to identify HE in its early stages, allowing for earlier intervention and better outcomes.
Key Takeaways from the Market Study
- The Hepatic encephalopathy treatment market is expected to grow at a value of 6.5% CAGR in the forecast period 2023-2033
- Hospital pharmacies are expected to hold 49% of the market share in 2023 for Hepatic encephalopathy treatment market.
- North America is expected to possess 44% market share for Hepatic encephalopathy treatment market in 2023.
- Asia Pacific Hepatic encephalopathy treatment market size is expected to possess 39% market share in 2023.
“The Hepatic Encephalopathy Treatment Market is also being driven by the increasing adoption of combination therapies for HE.” states an FMI analyst
Speak to our Research Expert: https://www.futuremarketinsights.com/ask-question/rep-gb-16814
Competitive Landscape
Key players in the hepatic encephalopathy treatment market are:
Mallinckrodt Pharmaceuticals, Salix Pharmaceuticals, GlaxoSmithKline plc., Pfizer Inc., ASKA Pharmaceutical Co., Ltd., Bausch Health, Johnson & Johnson Services, Inc., Janssen Global Services, Takeda Pharmaceutical Company Limited, Merck & Co., Inc.
- Mallinckrodt Pharmaceuticals has developed and marketed several medications for the treatment of Hepatic Encephalopathy that include Ofirmev and Terlipressin (Glypressin) injection. In addition to these medications, Mallinckrodt Pharmaceuticals has also sponsored clinical research into the treatment of HE, with a focus on developing new treatments and improving the understanding of the condition.
- Salix Pharmaceuticals has developed Xifaxan (rifaximin) tablets. Xifaxan is an antibiotic medication that works by reducing the levels of bacteria in the gut, which can help reduce the production of toxins that contribute to the development of HE.
Key Segments Profiled in the Hepatic Encephalopathy Treatment Industry Survey
Drug Class:
- Antibiotics
- Laxatives
- L-ornithine
- L-aspartate
Diagnosis:
- Blood Tests
- CT Scan
- Liver Functioning Tests
Route of Administration:
- Oral
- Injectable
- Intravenous
- Others
Distribution Channel:
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Grow your profit margin with FutureMarketInsights – Buy the report!
Table of Content
1. Executive Summary | Hepatic Encephalopathy Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
Complete TOC with Report Preview: https://www.futuremarketinsights.com/reports/hepatic-encephalopathy-treatment-market
Have a Look at Related Research Reports in the Healthcare Domain:
Viral Vector Development Market Size - The global market is expected to enjoy a valuation of US$ 730.7 Million by the end of the year 2023, and further expand at a CAGR of 18.7% to reach a valuation of ~US$ 4.1 Billion by the year 2033.
Sleep Apnea Devices Market Growth - The sleep apnea devices market is set to thrive at a steady CAGR of 9.5% during the forecast period. The market holds a share of US$ 8.2 billion in 2023 while it is anticipated to cross a value of US$ 20.4 billion by 2033.
Fiducial Markers Market Share - The global market is expected to enjoy a valuation of US$ 153.6 Million by the end of the year 2023, and further expand at a CAGR of 10.3% to reach a valuation of ~US$ 408.3 Million by the year 2033.
Gamma Probe Devices Market Trends - The global market is expected to enjoy a valuation of US$ 86.9 Million by the end of the year 2023, and further expand at a CAGR of 9.8% to reach a valuation of ~US$ 244.3 Million by the year 2033.
Uterine Manipulation Devices Market Outlook - The Uterine Manipulation Devices Market was valued at US$ 297.7 Million in 2022, and now it is expected to grow with a CAGR of 6.1% from 2023 to 2033.
About Future Market Insights, Inc.
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S., and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
LinkedIn| Twitter| Blogs | YouTube
For Sales Enquiries: sales@futuremarketinsights.com
